Lv61
1640 积分 2022-02-16 加入
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
1个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
1个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time-Of-Flight Mass Spectrometry
1个月前
已完结
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
1个月前
已完结
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
1个月前
已完结
10.1038/d41573-025-00091-1
3个月前
已完结
A new drug target for NRAS(Q61) mutant-expressing cancers
3个月前
已完结
RAS G12C Inhibitors: Three Birds with One Stone
4个月前
已完结
Tackling KRAS(G12C)-mutated non-small-cell lung cancer: iteration and exploration
4个月前
已完结
皖公网安备34019202002308
